NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Genelux Corporation (GNLX) Stock Analysis

Genelux Corporation (GNLX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

GNLX

$2.44

−$0.08 (−3.17%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GNLX with… →

GNLX Key Statistics

As of Sep 4, 2026
Trading
Open
$2.52
Previous Close
$2.52
Day's Range
2.43–2.54
52-Week Range
2.29–8.54
Volume
290.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.56
Valuation
Market Cap
$110.40M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.86
Financials (FY)
Revenue (FY)
$8.00K+0.00%
Net Income (FY)
−$32.15M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
45.25M
1-Year Return
−29.89%
Dividend and dates
Avg Volume
253.97K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

GNLX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−44.04%
2025+84.75%
2024−83.15%
2023+127.80%

As of September 4, 2026.

GNLX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$8.00K−$32.15M−401812.5%
2024$8.00K−$29.87M−373362.5%
2023$170.00K−$28.30M−16645.3%
2022$11.07M−$5.21M−47.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$8.00K—−$33.21M−$32.15M−401812.5%
2024$8.00K—−$31.70M−$29.87M−373362.5%
2023$170.00K—−$24.17M−$28.30M−16645.3%
2022$11.07M—−$3.01M−$5.21M−47.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

GNLX Valuation vs Biotechnology Median

Median of 656 stocks
MetricGNLXBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Genelux Corporation (GNLX) at $110.40M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 25 employees.

GNLX last closed at $2.44 on September 4, 2026. That is −$0.08 (−3.17%) against the previous close. The 52-week range on file runs from $2.29 to $8.54. The latest close sits 6.55% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $8.00K. That is 0.00% against the prior fiscal year, when revenue was $8.00K. The same year closed with a net loss of $32.15M. Profit margin runs at 0%. Trailing earnings per share are −0.86.

Across the 4 fiscal years on file, revenue moves from $11.07M in 2022 to $8.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 0.56. Annualized volatility over the trailing 3 years is 97.98%. Over the trailing twelve months the price has returned −29.89%. Measured over 3 years, that is −52.72% a year compounded.

Growth & Income

The record shows no dividend for GNLX.

2026 is still running; the price is −44.04% year to date. The strongest complete calendar year on file is 2023 at +127.80%; the weakest is 2024 at −83.15%. Of the 3 complete calendar years on file, 2 finished higher.

Peer Comparison

Genelux Corporation (GNLX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Genelux Corporation GNLX $110.40M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Genelux Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Genelux Corporation

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.

Visit website →